To include your compound in the COVID-19 Resource Center, submit it here.

Ardelyx's tenapanor meets in second Phase III for IBS-C

Ardelyx Inc. (NASDAQ:ARDX) plans to submit an NDA to FDA in 2H18 for tenapanor (AZD1722, RDX5791) to treat irritable bowel syndrome with constipation (IBS-C) after reporting that the compound met the primary and secondary endpoints in the Phase III T3MPO-2 trial.

On the 593-patient trial's

Read the full 444 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE